Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1121226.3Aexternal-prioritypatent/GB201121226D0/en
Priority claimed from GBGB1121233.9Aexternal-prioritypatent/GB201121233D0/en
Application filed by Glaxo Group LtdfiledCriticalGlaxo Group Ltd
Publication of CR20140077ApublicationCriticalpatent/CR20140077A/en
Preparation Of Compounds By Using Micro-Organisms
(AREA)
Abstract
La presente invención se refiere a proteínas y péptidosmodificados que tienen una capacidad reducida para unirse aanticuerpos preexistentes. Dichas moléculas de 5 proteína/péptidomodificadas pueden comprender adiciones, extensiones o etiquetas y/o determinadas sustituciones de aminoácidos en el extremo C terminal.The present invention relates to modified proteins and peptides that have a reduced ability to bind to preexisting antibodies. Said protein / peptide-modified molecules may comprise additions, extensions or labels and / or certain amino acid substitutions at the C-terminus.
CR20140077A2011-08-172014-02-17
PROTEINS AND MODIFIED PEPTIDES
CR20140077A
(en)
Polypeptide comprising a first amino acid sequence which in turn comprises at least one individual variable immunoglobulin domain that specifically binds to il-17f, il17-a / f, but not to il-17a, and a second amino acid sequence that it comprises at least one individual variable domain of immunoglobulin that specifically binds to il-17a, il-17f and il17-a / f; pharmaceutical composition that includes it; And its use.
Isolated antibody or a protein comprising an antigen binding portion of an antibody directed against a cd40 polypeptide; pharmaceutical composition comprising said antibody; nucleic acid encoding the antibody; cloning vector; antibody production process.
Antibody that binds antigenic peptide that is obtained from a tau protein; pharmaceutical composition comprising; use to treat neurodegenerative disorder or disease; test kit, cell line (div 2457-2011).
HYDROchloride salt of a peptide, pharmaceutical composition, use of a hydrochloride salt, use of a pharmaceutical composition, and method of preventing or treating cat allergy